Outcome measures | All patients with ARDS | Patients with COVID-19-related ARDS | Patients with ARDS from other causes | ||||||
---|---|---|---|---|---|---|---|---|---|
VAP (n = 176) | No VAP (n = 160) | Difference (95% CI) | VAP (n = 69) | No VAP (n = 32) | Difference (95% CI) | VAP (n = 107) | No VAP (n = 128) | Difference (95% CI) | |
MV duration, days | 17 (12–29) | 7 (5–10) | 10 (8; 12) | 22 (17–33) | 8 (7–13) | 14 (10; 17.5) | 15 (9–24) | 7 (5–10) | 8 (6; 10) |
Ventilator-free days at day 281 All patients ICU survivors | 0 (0–12) 11 (0–15) | 19 (0–22) 21 (18–23) | − 19 (− 20; − 13.5) − 10 (− 13; − 9) | 2 (0–11) b 7 (0–11.5) | 19 (11–21) 20 (16.5–21) | − 17 (− 20; − 9.5) − 13 (− 17; − 9) | 0 (0–14) b 12 (2–17) | 19 (0–22) 21 (19–23) | − 19 (− 20; − 10) − 9 (− 11; − 6) |
Vasopressor-free days at day 28 a | 18 (0–24) | 23 (0–27) | − 5 (− 9; − 2) | 18 (10–25) | 25 (20.5–28) | − 7 (− 11; − 1) | 16 (0–24) | 23 (0–26) | − 7 (− 15; − 2) |
ICU LOS, days a | 23 (16–36) | 10 (8–14) | 13 (9; 15) | 27 (19–41) | 11 (10–16) | 15 (11.5; 21.5) | 19 (13–28) | 10 (8–14) | 9 (7; 13) |
Hospital LOS, days a | 32 (21–48) | 21 (12–31) | 11.5 (7.5; 17.5) | 37 (25–50) | 21 (16–28) | 15.5 (11; 24) | 29 (17–47) | 20 (11–34) | 8.5 (2; 15) |
In-ICU mortality | 59 (33.5) | 43 (26.9) | 6.6 (− 3.2; 16.2) | 18 (26.1) | 6 (18.7) | 7.3 (− 11.5; 22.4) | 41 (38.3) | 37 (28.9) | 9.4 (− 2.6; 21.3) |
In-hospital mortality | 63 (35.8) | 45 (28.1) | 7.7 (− 2.3; 17.4) | 18 (26.1) | 6 (18.7) | 7.3 (− 11.5; 22.4) | 45 (42.1) | 39 (30.5) | 11.6 (− 0.7; 23.5) |
Mortality at day 90 c | 63 (35.8) | 48 (30.0) | 5.8 (− 4.3; 15.6) | 18 (26.1) | 6 (18.7) | 7.3 (− 11.5; 22.4) | 45 (42.1) | 42 (32.8) | 9.2 (− 3.1; 21.3) |